Otelixizumab is a monoclonal antibody (mAb) directed to human CD3ε, a protein forming part of the CD3/T-cell receptor (TCR) complex on T lymphocytes. This study investigated the temporal interaction between varying concentrations of otelixizumab, binding to human CD3 antigen and expression of CD3/TCR complexes on lymphocytes in vitro, free from the confounding influence of changing lymphocyte frequencies observed in vivo. A static in vitro culture system was established in which primary human peripheral blood mononuclear cells (PBMCs) were incubated over an extended time course with titrated concentrations of otelixizumab. At each time point free, bound and total CD3/TCR expression on both CD4+ and CD8+ T cells and the amount of free otelixizumab antibody in the supernatant were measured.
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Introduction
Monoclonal antibodies (mAb) directed against human lymphocyte antigen CD3ε have been investigated clinically in a number of autoimmune diseases such as type 1 diabetes (Herold et al., 2002; Keymeulen et al., 2005 , Hagopian et al., 2013 , ulcerative colitis (Sandborn et al., 2010) , multiple sclerosis (Weinshenker et al., 1991 ) and Crohn's disease (van der Woude et al., 2010) .
One such anti-CD3 mAb, muromonab-CD3 (tradename Orthoclone OKT3), is approved for the treatment of steroid-resistant acute rejection of allogeneic renal, heart and liver transplants.
Despite encouraging results from clinical investigations in autoimmune diseases, especially in new-onset type 1 diabetes, there has been little progress in understanding the relationship between anti-CD3 mAb target engagement and its putative mechanisms of action. Due to this lack of pharmacological understanding, dosage regimens appear to have been largely empirically determined, or when animal disease or in vitro models have been used for extrapolation, the ability to adjust for animal-human or in vitro-vivo differences was limited. The following pharmacology has been observed clinically with anti-CD3 mAbs: 1) binding leads to apparent partial T cell activation, resulting in release of pro-inflammatory cytokines, and a temporary disruption of normal T cell trafficking (Smith et al., 1997; Smith et al., 1998; Chatenoud et al., 1982; Waldron-Lynch et al., 2012) and 2): internalization of the resultant mAb/CD3/T cell receptor (TCR) complex causes loss of the complex from the T cell surface membrane and degradation and elimination of the antibody (Reinherz et al., 1982; Monjas et al., 2012; Liu et al., 2000; Press et al., 1988) , a phenomenon known as target-mediated drug disposition (Levy, 1994) . While some quantification of these clinical observations has been possible (Wiczling et al., 2010) , it has been difficult to separate and quantify these individual pharmacological components at a mechanistic level due to the close temporal relationship between them. JPET #224899 7 In an attempt to overcome the limitations of studying anti-CD3 mAb pharmacology in vivo, a static in vitro culture system was established to investigate the time course of the interaction between anti-CD3 mAb, CD3 and CD3/TCR complex, free from the confounding influence of changes in number of circulating T lymphocytes, as observed as transient peripheral lymphopenia in vivo. A mechanistic nonlinear mixed effect pharmacokinetic/pharmacodynamic model was then used to analyse and describe the complex pharmacological interactions in this static in vitro system. The in vitro pharmacokinetics (PK) was investigated in which primary human peripheral blood mononuclear cells (PBMCs) were used; CD3+ T lymphocytes in PBMCs is typically in the range of 50 -70%. PBMCs were cultured over an extended time course with titrated concentrations of otelixizumab. At each time point, free, bound and total CD3/TCR expression on both CD4+ and CD8+ T cells and the amount of free antibody in the supernatant were measured so that PK could be related to pharmacodynamic (PD) effects. To investigate the kinetics of CD3/TCR re-expression, cells were washed on day 2 to remove exogenous otelixizumab and thereby allow the rate of CD3/TCR complex re-expression to be monitored.
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Materials and Methods
Experimental design
PBMCs isolated from healthy volunteer bloods were cultured in the presence of a titration of otelixizumab over an extended time course (Figure 1 ). Flow cytometry was used to measure free and bound CD3ε and TCR at the indicated time points. Simultaneously, an ELISA was used to measure the amount of free antibody in the supernatant of these cultures. In addition some cells were washed to remove exogenous antibody after 2 days and measurement of CD3/TCR reexpression examined at the indicated time points post-wash.
Antibodies
Otelixizumab (also known as ChAglyCD3) is an aglycosylated non-mitogenic recombinant antibody (human γ 1) directed against CD3ε chain; a protein forming part of the CD3/T-cell receptor complex (TCR) on T lymphocytes (Routledge et al., 1991; Bolt et al., 1993) .
Otelixizumab reference standard at 12.1 mg/ml was used for all experiments.
Isolation of PBMC
Healthy volunteer bloods were obtained from the on-site blood donation unit and appropriate informed consent was obtained from all donors. Blood was withdrawn into bags containing 1U/mL sodium heparin (MP Biomedicals) as anti-coagulant. Heparinised blood was kept at room temperature and processed within 2 hours of withdrawal. PBMC separation was performed by density gradient centrifugation using 50 ml Leucosep tubes (Greiner Bio-One) containing FicollPaque. 25 ml of blood per tube were centrifuged for 20 minutes at 800g with the brake off.
PBMCs recovered from the interface were washed twice with Dulbecco's Phosphate Buffered This article has not been copyedited and formatted. The final version may differ from this version. Saline (PBS) (GIBCO) and finally resuspended in complete medium for counting using the Guava EasyCyte. Complete medium comprised RPMI 1640 (Gibco) + 1mM Glutamine (Gibco), 100 U/ml penicillin/100 µg/ml streptomycin (Gibco) and 5% heat inactivated human AB serum (Gemini Bioproducts).
Time course of PBMC treatment with otelixizumab.
Freshly isolated PBMC from two healthy donors (1x10 6 /ml) were cultured in 24 well plates (Costar) in RPMI + 5% AB serum with titrated concentrations of otelixizumab (0, 1, 3, 10, 30, 100, 300, 1,000, 3,000 and 10,000 ng/ml) 16 wells for each concentration. At time points 0. 25, 0.5, 1, 2, 4, 8, 16 hours and 1, 2, 3, 4, 6, 8, 10, 12 and 14 days the cell suspension was removed from one well for each donor transferred to FACS tubes and centrifuged 5 minutes at 1350 rpm.
The supernatant was removed and stored for subsequent ELISA at -20°C and the cells were resuspended in 4ml FACS buffer and split between 2 tubes for FACS staining. For CD3/TCR reexpression PBMC from each donor were cultured at 1x10 6 /ml (10 ml) in RPMI + 5% AB serum with the same titrated concentrations of otelixizumab. After 48 hours cells were removed from wells and transferred to 50 ml tubes and centrifuged 1350 rpm for 5 minutes. Cells were resuspended in 50 ml PBS and centrifuged again. After resuspending in fresh RPMI + 5%AB 
In vitro PK-PD model
A TMDD model (Mager and Jusko, 2001 ) accounting for otelixizumab binding on both CD4+
and CD8+ lymphocytes was proposed to describe in vitro experimental data including the extension of two binding sites (Gibiansky and Gibiansky, 2010) . The proposed model is illustrated in Fig. 2 .
Otelixizumab (here denoted by Cp) is administered in the central compartment where it can bind to free CD3/TCR receptor complex on both CD4+ and CD8+ lymphocytes (FR4 and FR8, respectively) to form drug-receptor complexes (DR4 and DR8, respectively).
The model is described through the following differential equations expressed as molar concentrations:
with initial conditions given by
This article has not been copyedited and formatted. The final version may differ from this version. Assuming equal otelixizumab binding to CD4+ and CD8+ lymphocytes, the model can be simplified by imposing equal association and dissociation rate constants (i.e. kon4=kon8=kon
and koff4=koff8=koff).
Otelixizumab molar concentration was converted into the observed concentration (ng/ml) using its molecular weight (150 kDa) and appropriate scaling (apparent volume of distribution V).
Receptor dynamic measurements were expressed in MESF units that are assumed to be proportional to receptors molar concentrations. Otelixizumab bound to CD3 blocks the binding of all available anti-TCR and anti-CD3 detection antibodies that were tested. As a consequence, free and total receptors could be detected only where otelixizumab was not bound to CD3. This implied that total receptor measurements (MTR4 and MTR8) were proportional to free receptors molar concentration (and not to the sum of free and bound receptor concentrations): The PK/PD model was fitted to the individual PK and PD (free, engaged and total CD3/TCR receptors) data simultaneously using non-linear mixed-effect statistical analysis. Model development included differences for the two donors in baseline values for CD4+ and CD8+ T lymphocytes and different otelixizumab affinities for binding respectively on CD4+ and CD8+ T lymphocytes. Additive, proportional and combined residual error models were tested for each 
Results
Pharmacokinetics of Free Otelixizumab
In order to describe pharmacological interactions in a static in vitro culture system, the pharmacokinetics of otelixizumab was investigated. Free otelixizumab concentration time-course profiles are shown in Fig. 3 from two donors at different initial drug concentrations over a 48hr incubation period. At initial drug concentrations higher than 100ng/ml, otelixizumab concentration levels were relatively static over 48 hours. In contrast, there was an apparent initial concentration-dependent and time-dependent reduction in free otelixizumab concentrations, observed with both donors at initial concentrations lower than 100ng/ml. At the lowest starting concentrations (3 and 1ng/ml), free otelixizumab concentrations were below the limit of quantification (BLQ) for both donors. Some values were obtained by extrapolation of the standard curve at early time points but antibody was undetectable at later time points.
Collectively, these observations suggest target-mediated elimination of otelixizumab in this system.
Pharmacodynamics of free/bound CD3 and Total CD3 Expression
Next, the in vitro pharmacodynamic time courses of free and bound CD3ε together with total CD3ε expression on CD4+ and CD8+ T lymphocytes in the PBMC culture following incubation with otelixizumab were determined. CD4+ T lymphocytes pharmacodynamic time course profiles selected initial concentrations for donor 1 are shown in Fig. 4 . Free CD3ε and total CD3ε expression followed similar time courses. There was a rapid decline in both free CD3ε and total
CD3ε expression relative to pre-incubation levels. In both cases, the rate and extent of reduction appeared to increase with higher initial concentrations with the nadirs occurring as early as 0.25
This article has not been copyedited and formatted. The final version may differ from this version. Following washout of otelixizumab post-48 hours, there was a gradual but steady increase in free
CD3ε and re-expression of total CD3ε. Based on visual inspection of the data, the rate of reexpression of total CD3ε appeared to be similar for all initial concentrations and independent of the degree of reduction of CD3ε expression induced by incubation with otelixizumab. For low initial concentrations (<30ng/mL) expression levels returned to pre-incubation levels by approximately Day 6 following wash out of otelixizumab. In contrast, at the highest initial concentration (10,000ng/mL) expression had recovered to only around 80% of pre-incubation levels by the end of the experiment (day 14). Again, results were consistent for both CD4+ and CD8+ cells and comparable between donors (data not shown).
Characterisation of the Pharmacokinetic/Pharmacodynamic -Time Relationship
Mechanistic, mathematical, TMDD PK/PD models were fitted simultaneously to the PK and PD (free, engaged and total CD3/TCR receptors) data. In terms of the model iteration and adequacy, the most robust best fit model included different baseline levels for CD3/TCR on CD4+ and CD8+ T lymphocytes (BAS4 and BAS8 respectively) for the two donors. The final model did not include any between-subject variability on model parameters, so that the resulting analysis can be considered as a naïve-pooling approach. The binding affinities for otelixizumab for CD3ε on CD4+ or CD8+ lymphocytes were found to be similar and the model was simplified by assuming equal affinity for both lymphocyte subsets (i.e. kon4=kon8=kon and koff4=koff8=koff).
This article has not been copyedited and formatted. The final version may differ from this version. and all initial concentrations of otelixizumab, (Fig. 3-4) .
The parameter estimates for the model are reported in Table 1 
Discussion
We established a static in vitro culture system to investigate and characterize otelixizumab pharmacology using human cells. We were able to study the dose range and time course with sufficient resolution to observe and quantify the concentration and time-dependent pharmacokinetic behavior consistent with target-mediated disposition of the antibody. A mechanistic, mathematical model (TMDD model), used to describe this phenomena, was fitted to the pharmacokinetic and pharmacodynamics-time data. The model adequately described all the data and was sufficient to explain the nonlinear disposition of otelixizumab in this culture system. The rate and degree of change of free, bound and total CD3ε expression was found to be determined by the concentration of otelixizumab. A moderate increase was observed in total CD3/TCR receptor profiles at the end of the experiment. Although data described in this paper does not allow any conclusion regarding the cause of this modest increase, it is possible that a small degree of cell death (approximately 10% was observed during the 14 day culture) is a contributing factor. This was however not considered a relevant feature to implement in the final model as judged to be relatively minor compared to the degree of CD3/TCR decreases rapidly achieved following otelixizumab engagement. Although the use of a constant synthesis rate for CD3/TCR receptors do not account for possible changes in cell culture compositions due to cell death, the proposed model captured the concentration-dependent kinetic profiles for free, bound and total CD3ε reasonably well. At saturating concentrations, the engagement of target CD3ε molecules was found to be rapid leading to full occupancy of CD3ε within minutes. At lower This phenomenon is a common mechanism when natural ligand binds to its corresponding receptor and has been described for antigen binding to the T cell receptor (Huang et al 1999) , and the B cell receptor (Caballero 2006 ) and for ligand binding to the GM-CSF receptor (Vainshtein, 2015) . Following removal of antibody from the culture, the rate of re-expression of CD3ε was observed to be slower than otelixizumab-induced down regulation. Model estimates for internalization and degradation rate constants for CD3/TCR receptors reflect these findings. At
This article has not been copyedited and formatted. The final version may differ from this version. saturating concentrations, complete modulation was achieved within about 30 minutes, whereas full CD3/TCR re-expression to pre-treatment levels required about 8 days.
These findings are in agreement with data obtained from mouse models using surrogate anti-CD3 antibody fragments (Mehta et al., 2010) . These observations are supportive of the notion that CD3ε re-appearance requires new synthesis and assembly of complexes, known to be a slow process that takes days, as opposed to re-expression of transiently internalized existing complexes which has been described as a relatively rapid process (minutes/hours) (Menné et al., 2002) . It should be noted that the exact fate of otelixizumab was not investigated in this study.
Several mechanisms are possible, with some studies demonstrating endocytosis of antibody receptor complexes (Monjas et al.,2012; Liu et al., 2000; Kuhn et al.,2011) while others suggest shedding of the complex from the cell surface (Reinherz et al., 1982; Press et al., 1988) .
In contrast, despite considerable investigation, the degree, duration of action of otelixizumab binding to CD3ε, CD3 expression and its relationship to unbound antibody has only been partially elucidated from clinical data alone. For practical reasons, it has been difficult to study a sufficiently wide dose range with an adequate blood sampling schedule following treatment of otelixizumab in patients to determine whether the dynamics of antibody binding can be separated from the dynamics of the observed transient lymphopaenia. Thus, attempts to quantify these relationships clinically have been largely empiric and simple (Wiczling et al., 2010) . While the published models describe the data adequately, and may be useful for limited interpolation or extrapolation, they lack the mechanistic detail to provide insight about the underlying pharmacological behavior of otelixizumab. Understanding the in vivo interaction of otelixizumab to the CD3 target is challenging since observed data may not be sufficient to estimate relevant system parameters. In this case, the in vitro model can provide relevant information for the receptor synthesis (ksyn), degradation/internalisation rate (kdeg and kint) and binding affinity (KD) that can help to better inform any in vivo model where other phenomena (mAb distribution, disposition and systemic clearance due non-specific target binding, together with target expression, lymphocytes trafficking etc) would increase the complexity of the model structure including identifiability issues for relevant system parameters. In general, the development of mechanistic models from in vitro experiments offers a valuable approach to address the complexity of in vivo systems by using, for example, the in vitro estimates as priors for the in vivo models.
Pre-clinical investigation of these phenomena in vivo, is limited by the almost complete lack of cross-reactivity of otelixizumab with animal CD3 and lack of suitable animal surrogate antibody.
In conclusion, we have demonstrated using an in vitro cell culture system and a mechanistic model-based approach to data analysis, that we can successfully study and quantify the complex antibody-receptor complex PK/PD interactions that were hypothesized for otelixizumab. This is likely to be applicable to other membrane-bound targets, particularly for immune cell targets where antibodies or other protein therapeutics may cause altered cell trafficking. The parameters estimated from such analysis may allow investigators to compare and contrast with other data, and the models can be used to design dosage regimens and optimize sample schedules for future clinical_trials.
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